Statistics from Altmetric.com
Crossover randomised controlled trial.
Follow up period:
Five university outpatient centres, USA; recruitment November 2001 to September 2003.
Sixty six children (89% male) aged 5–14 years with DSM-IV autism, Asperger’s syndrome, or unidentified pervasive development disorder plus hyperactivity and/or impulsiveness for ⩾6 months with onset before age 7. Exclusions: receiving psychotropic medication in previous 1–3 weeks; mental age <18 months; other neuropsychiatric disorders; moderate or severe tic disorder; seizures in the past six months; hypertension; other serious medical comorbidity; methylphenidate treatment in previous two years; previous adverse reaction to …
For correspondence: David J Posey, MD, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202, USA;
Sources of funding: Korczak Foundation, Netherlands and National Institute of Mental Health and National Institute of Health, USA.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.